Director of PK/PD Core Facility
Department of Medicine
Roswell Park Cancer Institute
Adjunct Assistant Professor
Department of Pharmaceutical Sciences

Dr. Fetterly received his doctoral degree in Pharmaceutics from the University at Buffalo in 2000. He possesses considerable expertise in developing oncology agents and the liposomal encapsulation of drugs. Specifically, his doctoral work and subsequent publications focused on an extensive comparison of the PK/PD relationships of various anticancer drugs, such as liposomal paclitaxel, trabectedin, and mTOR inhibitors.

Dr. Fetterly has developed both preclinical and clinical PK/PD models to characterize the temporal relationship between the PK of the drug in relation to the time course of drug related pharmacodynamic endpoints such as neutropenia and transaminase elevation. 

Prior to joining Roswell Park Cancer Institute, Dr. Fetterly worked at Cognigen where he performed population PK/PD modeling among other projects, and provided consulting services for both industry and academia to assess the impact of patient factors that are sources of variability in not only pharmacokinetics but also the PK/PD relationships for both efficacy and safety, mainly for oncology and neuropharmacology drugs. At Cognigen, he led and managed interdepartmental projects in Clinical Pharmacology, provided sparse sampling designs for clinical pharmacology trials, provided clinical pharmacology services for regulatory strategy during Advisory Board and Sponsor/FDA meetings, reviewed the non-clinical as well as clinical pharmacology development sections of various INDs and NDAs, as well as assisted in the interpretation of preclinical data and extrapolation of implications for human clinical development utilizing PK/PD modeling approaches. 

From 2000-2002, Dr. Fetterly was a clinical pharmacology and biopharmaceutics reviewer at the FDA.